University Hospitals (UH) Case Medical Center has announced a $250 million initiative that promises to dramatically change how drugs will advance from discovery in the laboratories to commercialization, resulting in greater access to advanced treatments and cures for patients. The first-of-its-kind initiative, named The Harrington Project for Discovery & Development, is powered by a $50 million gift – the largest donation in the health system’s history – from the Harrington family, recognized entrepreneurs and philanthropists in Cleveland.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54909-university-hospitals-uh-harrington-discovery-institute-development-project
Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, today announced the opening of its new environmentally friendly corporate headquarters in Philadelphia’s Navy Yard Corporate Center. This milestone is part of the Company’s long-term growth plan as it advances its late-stage pipeline of lower dose submicron non-steroidal anti-inflammatory drugs (NSAIDs) towards commercialization.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58559-iroko-pharmaceuticals-opens-philadelphia-headquarters-hq
Hallmark Signature Collection holiday cards are truly unique, just like a signature. The exquisite textures, premium quality paper, fun embellishments, and relevant messages are sure to help Hallmark Signature Collection cards become holiday favorites to place on the mantle and be appreciated for several seasons.
“These cards are perfect for shoppers who like sophisticated, dimensional designs,” said Dan Foster, Hallmark Vice President of Creative Commercialization Greetings. “Consumers told us they wanted cards that were meaningful and authentic, as well as surprising, unexpected, and appropriate for a keepsake.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/59627-hallmark-signature-collection-holiday-cards-a-distinctive-experience
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Daimler AG, Ford Motor Company and Nissan Motor Co., Ltd., have signed a unique three-way agreement to accelerate the commercialization of fuel cell electric vehicle (FCEV) technology.
The goal of the collaboration is to jointly develop a common fuel cell electric vehicle system while reducing investment costs associated with the engineering of the technology. Each company will invest equally towards the project. The strategy to maximize design commonality, leverage volume and derive efficiencies through economies of scale will help to launch the world’s first affordable, mass-market FCEVs as early as 2017.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58680-renault-nissan-daimler-ford-partnership
